Literature DB >> 33624254

Inflammation, Obsessive-Compulsive Disorder, and Related Disorders.

Jeffrey Meyer1,2.   

Abstract

Initial reports supporting the possibility of inflammation in the brain in obsessive-compulsive disorder (OCD) evolved from the models of Sydenham's Chorea, and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS), which implicated excessive autoimmune responses following exposure to group A B-hemolytic streptococcal infections. Subsequently, this model was expanded to Pediatric Autoimmune Neuropsychiatric Syndrome (PANS) which applied the same concept but included other infections. A critical shortcoming of this model was that it was attributable to a small minority of OCD cases. The relationship between inflammation and OCD was more broadly demonstrated through translocator protein (TSPO) positron emission tomography imaging, a method that detects gliosis, an important component of brain inflammation, in neuropsychiatric diseases, including morphological activation and proliferation of microglia and to some extent astroglia. This method identified greater TSPO binding in the cortico-striatal-thalamo-cortical circuit in OCD, providing a direct brain measure of an important component of inflammation. To identify OCD cases with prominent elevations in TSPO binding in clinical research settings with lower cost peripheral markers, a promising approach is to apply blood serum biomarkers of inflammatory molecules produced by activated microglia and astroglia (gliosis). Such measures may aid stratification in future clinical trials. Several inflammatory-modifying interventions, including celecoxib, minocycline, and n-acetylcysteine, have been tested as treatments in randomized double-blind placebo controlled clinical trials and there is a tendency toward positive results, although these medications are not optimized for brain penetration and sample sizes for most trials were small. Future clinical trials of medications that target gliosis in OCD should apply larger sample sizes, ideally incorporating stratification approaches to enrich samples for the presence of gliosis.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoimmune; Gliosis; Neuroinflammation; Obsessive-compulsive disorder

Mesh:

Substances:

Year:  2021        PMID: 33624254     DOI: 10.1007/7854_2020_210

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  88 in total

1.  PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia.

Authors:  R B Banati; R Myers; G W Kreutzberg
Journal:  J Neurocytol       Date:  1997-02

2.  Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder.

Authors:  Sophia Attwells; Elaine Setiawan; Pablo M Rusjan; Cynthia Xu; Celeste Hutton; Dorsa Rafiei; Benjamin Varughese; Alan Kahn; Stephen J Kish; Neil Vasdev; Sylvain Houle; Jeffrey H Meyer
Journal:  Biol Psychiatry       Date:  2020-03-29       Impact factor: 13.382

3.  Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei.

Authors:  Karen H Adams; Elsebeth S Hansen; Lars H Pinborg; Steen G Hasselbalch; Claus Svarer; Søren Holm; Tom G Bolwig; Gitte M Knudsen
Journal:  Int J Neuropsychopharmacol       Date:  2005-04-01       Impact factor: 5.176

4.  Transporter-mediated prostaglandin E₂ elimination across the rat blood-brain barrier and its attenuation by the activation of N-methyl-D-aspartate receptors.

Authors:  Shin-ichi Akanuma; Takanori Higuchi; Hideyuki Higashi; Go Ozeki; Masanori Tachikawa; Yoshiyuki Kubo; Ken-ichi Hosoya
Journal:  Drug Metab Pharmacokinet       Date:  2014-04-08       Impact factor: 3.614

5.  Replicating predictive serum correlates of greater translocator protein distribution volume in brain.

Authors:  Sophia Attwells; Elaine Setiawan; Alan A Wilson; Pablo M Rusjan; Laura Miler; Cynthia Xu; Celeste Hutton; Muhammad I Husain; Stephen Kish; Neil Vasdev; Sylvain Houle; Jeffrey H Meyer
Journal:  Neuropsychopharmacology       Date:  2019-11-04       Impact factor: 7.853

Review 6.  The blood-brain barrier in neuroimmunology: Tales of separation and assimilation.

Authors:  W A Banks
Journal:  Brain Behav Immun       Date:  2014-08-27       Impact factor: 7.217

7.  Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus.

Authors:  Elizabeth A Bachen; Margaret A Chesney; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2009-06-15

Review 8.  The promise of N-acetylcysteine in neuropsychiatry.

Authors:  Michael Berk; Gin S Malhi; Laura J Gray; Olivia M Dean
Journal:  Trends Pharmacol Sci       Date:  2013-01-29       Impact factor: 14.819

9.  Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder.

Authors:  Funda Akkus; Sylvia Terbeck; Simon M Ametamey; Michael Rufer; Valerie Treyer; Cyrill Burger; Anass Johayem; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Int J Neuropsychopharmacol       Date:  2014-05-15       Impact factor: 5.176

10.  N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Hamid Afshar; Hamidreza Roohafza; Hamid Mohammad-Beigi; Mohammad Haghighi; Leila Jahangard; Pedram Shokouh; Masoumeh Sadeghi; Hasan Hafezian
Journal:  J Clin Psychopharmacol       Date:  2012-12       Impact factor: 3.153

View more
  2 in total

1.  Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis.

Authors:  Taro Kishi; Kenji Sakuma; Nakao Iwata
Journal:  Transl Psychiatry       Date:  2022-06-28       Impact factor: 7.989

Review 2.  Immunopsychiatry - Innovative Technology to Characterize Disease Activity in Autoantibody-Associated Psychiatric Diseases.

Authors:  Niels Hansen
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.